AbbVie's Parkinson's disease drug meets main goal in late-stage study-March 2024-www.financetom.com

AbbVie's Parkinson's disease drug meets main goal in late-stage study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

AbbVie's Parkinson's disease drug meets main goal in late-stage study

Dec 9, 2024 5:36 AM

Dec 9 (Reuters) - AbbVie ( ABBV ) said on Monday its

experimental drug to treat Parkinson's Disease met the main goal

in a late-stage study.

(Reporting by Mariam Sunny in Bengaluru; Editing by Anil

D'Silva)

Previous page： --Pfizer Fails to Stop Novo Nordisk's Metsera Bid in Delaware Court, Bloomberg Reports Next page： --Sprott Increases Quarterly Dividend to $0.40 from $0.30 per Share; Payable Dec. 2 to Shareholders of Record on Nov. 17

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Pfizer Fails to Stop Novo Nordisk's Metsera Bid in Delaware Court, Bloomberg Reports

Nov 4, 2025

01:21 PM EST, 11/04/2025 (MT Newswires) -- Price: 24.33, Change: -0.34, Percent Change: -1.36 ...

--Sprott Increases Quarterly Dividend to $0.40 from $0.30 per Share; Payable Dec. 2 to Shareholders of Record on Nov. 17

Nov 4, 2025

01:24 PM EST, 11/04/2025 (MT Newswires) -- Price: 81.54, Change: -0.19, Percent Change: -0.23 ...

Shell Secures 15-Year LNG Deal With UAE's ADNOC

Nov 4, 2025

Shell PLC ( SHEL ) shares are trading lower on Tuesday. The company’s subsidiary, Shell International Trading Middle East Limited FZE, penned a 15-year deal with Abu Dhabi National Oil Company (ADNOC). The deal involves delivery of up to 1 million tons per annum (mtpa) of liquefied natural gas (LNG). The LNG will mainly come from the Ruwais LNG project...

BRIEF-Global Bioenergies Says Takeover Offers Review Postponed To November 24, 2025

Nov 4, 2025

Nov 4 (Reuters) - Global Bioenergies SA: * GLOBAL BIOENERGIES SA - TAKEOVER OFFERS REVIEW POSTPONED TO 24 NOVEMBER 2025 * GLOBAL BIOENERGIES SA - UNABLE TO CLOSE HY FINANCIAL STATEMENTS DUE TO UNCERTAINTY SURROUNDING OUTCOME OF ONGOING PROCESS Source text: Further company coverage: ...